Andrew Paul Mazar - 31 Mar 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Chief Scientific Officer, Director
Issuer ticker: MNPR
Reported as of: 31 Mar 2022
Net transaction value: -$1,201
SEC form: 4
Accepted by SEC: 01 Apr 2022, 17:28:29 UTC
Prior SEC filing: 04 Feb 2022
Next SEC filing: 12 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Kim R. Tsuchimoto, Attorney-in-fact

Key filing fact

Andrew Paul Mazar filed Form 4 for Monopar Therapeutics (MNPR) on 01 Apr 2022.

Key facts

This page summarizes Andrew Paul Mazar's Form 4 filing for Monopar Therapeutics (MNPR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2022, 17:28.

Change

Previous filing in this sequence was filed on 04 Feb 2022.
Current net transaction value: -$1,201.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,606
Change %: +7.7%
Price
Shares after: 22,596
Date: 31 Mar 2022
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Tax liability

Transaction value: $1,201
Shares: -471
Change %: -2.1%
Price: $2.55
Shares after: 22,125
Date: 31 Mar 2022
Ownership: Direct

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,111,273
Date: 31 Mar 2022
Ownership: See Footnote
Footnotes: F2

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 166,667
Date: 31 Mar 2022
Ownership: See Footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,606
Change %: -1.8%
Price: $0.000000
Shares after: 88,792
Date: 31 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,606
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares acquired on vesting and settlement of restricted stock units.

Footnote F2

This is based upon the 4,111,272.88 shares of Monopar Common Stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Mazar disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.

Footnote F3

This is based upon the 166,667 shares of Monopar Common Stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Mazar disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.

Footnote F4

On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.